![]() |
市場調查報告書
商品編碼
1847178
全球胃腸內視鏡設備市場:市場規模、佔有率和趨勢分析(2025-2032 年)Gastrointestinal Endoscopic Device Market Size, Share & Trends Analysis | Global | 2025-2032 | Includes: GI Endoscopes, Capsule Endoscopy, Stenting and Dilation Devices, and 7 more |
||||||
※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。
2025 年全球胃腸內視鏡設備市場價值約為 163 億美元,預計到 2031 年將超過 215 億美元,年複合成長率為 4.0%。
本報告涵蓋胃腸內視鏡、膠囊內視鏡、支架置入和擴張裝置、ERCP裝置、切片檢查鉗和息肉切除勒除器、EUS穿刺針、內視鏡黏膜下剝離術(ESD)刀、止血裝置、經腸營養裝置和反流預防裝置。本研究量化了銷售量、平均售價(ASP)、市場規模、成長率和企業市場占有率,並分析了手術量、成長促進因素和阻礙因素、近期併購活動、產品系列和競爭格局。預測期至2031年,歷史資料截至2021年。
成長的促進因素包括篩檢和早期檢測項目的增加、全球人口老化以及影像處理、治療配件、一次性平台等方面的技術升級。預計新興地區醫療保健服務的普及將促使診斷性大腸鏡檢查、ERCP、EUS 和治療性胃腸道介入等手術數量的增加。
市場概覽
胃腸內視鏡檢查在胃腸道疾病的檢測和治療中起著至關重要的作用。大腸鏡檢查是大腸直腸癌篩檢和息肉切除的主要手段,而上消化道內視鏡檢查則用於處理出血、狹窄和逆流相關疾病。諸如ERCP、ESD和EUS引導下介入等治療性操作,已將內視鏡檢查的功能從診斷擴展到複雜的治療領域。
市場價值由資本設備、可重複使用和一次性醫療器材以及大批量耗材共同驅動。資本基礎包括胃腸內視鏡和視訊處理器。切片檢查鉗、息肉切除勒除器、支架、球囊和止血裝置等高通量產品類別帶來持續收入。膠囊內視鏡為小腸成像提供了一種非侵入性途徑,而經腸營養裝置則支持急性和慢性護理環境中的營養管理。
醫療機構正在從標準成像升級到高清和高清+成像,並在預算允許的情況下選擇性地採用4K和放大成像技術。一次性內視鏡因其在感染控制和工作流程方面的優勢,在特定場所越來越受歡迎。同時,結構化的全國性篩檢計畫正在擴大接受胃腸道疾病診療的人群,從而支持該診療的穩定成長。
成本控制仍然是至關重要的因素。在成熟市場,集團採購組織和競標模式正在降低平均售價,而醫院預算則推動了一次性醫療器材的逐步普及。然而,隨著臨床醫生尋求創傷較小的治療方法開放性手術方案,以及內視鏡治療循證醫學證據的不斷積累,對先進治療的需求仍在持續成長。
隨著基礎設施的改善、培訓的普及和公眾意識的提高,亞太和拉丁美洲等新興地區預計將在全球設備銷售中佔更大的佔有率。在這些市場,內視鏡實驗室和影像處理設備的成長將為診斷和治療程序提供支援。
市場促進因素
癌症發生率
大腸直腸癌是全球最常見的癌症之一,也是癌症相關死亡的主要原因。人口老化和公眾意識的提高正在推動篩檢計畫的參與率不斷上升。每5至10年進行一次大腸鏡檢查可以發現並切除癌前息肉,從而降低癌症風險。篩檢參與率的提高也帶動了對大腸鏡、切片檢查器械、勒除器和止血器械等設備的持續需求。
篩檢和早期檢測項目
政策調整和國家計畫正在擴大篩檢覆蓋範圍。在美國,美國預防服務工作小組(USPSTF)將大腸癌篩檢的建議起始年齡從50歲降至45歲,增加了大腸鏡篩檢的數量。英國國民醫療服務體系(NHS)已將腸道篩檢的起始年齡從60歲降至50歲。在韓國,一項國家計畫每兩年進行一次糞便免疫化學檢測(FIT),並對陽性結果進行大腸鏡檢查。此類項目能夠帶來可預測的、規律的篩檢量,支持內視鏡和耗材的穩定採購,並鼓勵採用能夠提高息肉檢出率的先進影像技術。
新技術開發
高清和高清+影像的升級,以及放大倍率和更優異的光學性能,正在提高診斷準確性。軟性內視鏡更易於操作,專用配件則可實現更精準的治療。一次性使用平台降低了交叉感染的風險,並簡化了再處理流程。值得關注的產品包括波士頓科學公司的Exalt Model D一次性十二指腸鏡和Ambu公司的aScope系列產品。同時,3D視覺化和4K影像處理也在針對特定應用場景進行評估。隨著這些技術的成熟和成本障礙的降低,預計產品銷售和手術量將會增加。
新興地區的擴張
亞太地區和拉丁美洲的醫療保健投資正在增加內視鏡實驗室、培訓計畫和轉診途徑的數量。都市化和收入成長正在改善醫療保健服務的可近性。人們對胃腸道疾病的認知不斷提高,篩檢的普及率不斷上升,推動了相關手術數量的增加,進而帶動了對內視鏡、ERCP設備、EUS穿刺針和止血器械的需求。
治療範圍和效率
內視鏡目前可用於治療出血、取出結石、擴張狹窄、切除早期癌症、修復缺損。拓展治療範圍將使潛在市場超越篩檢和診斷的範疇。人工智慧輔助的息肉檢測、改良的止血裝置以及更快捷的ERCP結石處理工具將提高效率,縮短手術時間,提高手術量,從而推動內視鏡技術的廣泛應用。
市場限制
集團採購組織
集團採購組織 (GPO) 和競標匯總了需求,從而壓低了價格。批量承諾和積極的折扣策略有利於擁有廣泛產品線的大型供應商。這些動態限制了利基市場參與者的市場准入,並壓縮了平均售價 (ASP),尤其對於大規模生產的消耗品更是如此。
替代篩檢
人們對侵入性較小的篩檢方法越來越感興趣,例如糞便免疫化學檢測(FIT-DNA)、血液檢測和膠囊內視鏡檢查。這些方法可以降低初次篩檢的門檻。然而,即使初次篩檢結果呈陽性,仍需進行大腸鏡檢查以確診和治療,內視鏡檢查仍將發揮核心作用。即使初次篩檢在一定程度上有所改變,後續的大腸鏡檢查仍然必不可少,因此對大腸鏡銷售的影響有限。
對採用新技術猶豫不決
臨床醫生對採用新設備持謹慎態度。許多醫療機構希望在改變診療流程之前,獲得確鑿的臨床效益和工作流程契合度證據。成本和培訓時間也是阻礙設備推廣的因素。例如,一次性使用平台必須透過感染控制和效率提升來證明其成本的合理性。隨著時間的推移,有利的研究和更完善的採購模式可以促進設備的推廣,但這需要一個循序漸進的過程。
預算限制和再加工投資
近期已投資於醫療設備再處理和設備的醫院,需要明確的價值論證才會考慮改用一次性設備和高階配件。新興地區的預算優先考慮高效益項目,這可能會延緩先進影像處理和專用工具的採用。
目標市場和數據範圍
醫療機構包括醫院、門診內視鏡中心、門診手術中心和專科診所。
目標市場及區隔
胃腸內視鏡市場
膠囊內視鏡市場
支架和擴張市場
內視鏡逆行性胰造影(ERCP)設備市場
切片檢查鉗和息肉切除勒除器市場
EUS針頭市場
內視鏡黏膜下剝離刀市場
止血設備市場
經腸營養設備市場
回流防止裝置市場
針對每個區隔市場分析市場價值、平均售價、銷售量、成長率和企業市場占有率,提供歷史趨勢和到 2031 年的預測展望。
競爭分析
奧林巴斯在胃腸內視鏡市場和內視鏡黏膜下剝離術(ESD)刀領域保持領先地位。同時,在膠囊內視鏡、ERCP器械、切片檢查鉗、息肉切除器、EUS穿刺勒除器和止血器械等領域也擁有較高的市佔率。如此豐富的產品線確保了奧林巴斯在整體市場中的領先地位。奧林巴斯憑藉其耐用、高品質的圖像、龐大的裝置量以及全面的服務和培訓支持,持續贏得客戶的讚譽。
2025年,波士頓科學公司在眾多配件類別中佔領先地位,超越其他任何競爭對手。該公司在支架置入和擴張器械、ERCP器械、切片檢查鉗和息肉切除勒除器、EUS穿刺針以及止血器械領域均佔領先佔有率,並在ESD刀領域保持著競爭優勢。 AXIOS™腔內引流支架和Exalt Model D一次性十二指腸鏡(解決了ERCP術後器械再處理難題)是推動公司成長的主要動力。這些產品有助於提高手術效率並控制感染,從而持續受到市場的青睞。
富士軟片在胃腸內視鏡市場佔第二大市場佔有率,整體排名第三。憑藉其強大的影像處理能力、產品可靠性和不斷豐富的治療配件產品線,富士膠片鞏固了其在醫院和門診中心的地位。富士膠片的整體市佔率略微超過了Avanos Medical。
其他參與企業在膠囊內視鏡、經腸營養、反流預防裝置等區隔領域競爭。在價格敏感的地區,當地製造商提供以價值為導向的耗材,而全球領導者則在影像處理、培訓和全線服務方面保持優勢。
科技與臨床趨勢
這些趨勢有助於提高內視鏡實驗室的吞吐量,實現更一致的結果,並治療更廣泛的疾病。
地區
其涵蓋範圍包括北美、歐洲、亞太地區、拉丁美洲以及中東和非洲。
胃腸內視鏡設備市場中最大、成長最快的機會是什麼?
篩檢計劃和人口老化將如何影響大腸鏡檢查和治療性內視鏡檢查的需求。
哪些技術升級,例如一次性平台、人工智慧輔助工具和進階影像處理,將獲得市場佔有率?
GPO和競標模式將如何影響大中小型製造商的定價和市場准入?
ERCP、EUS、ESD 和膠囊內視鏡檢查的流程預計會發生哪些變化,這些變化將如何影響輔助設備的消耗?
奧林巴斯、波士頓科學和富士膠片在資本和配件領域的定位。
哪些風險可能會減緩推廣應用,例如預算限制、替代篩檢以及臨床醫生的猶豫不決?
供應商如何調整培訓、服務和庫存以支持新興地區的成長?
iData Research 的「全球胃腸內視鏡設備市場報告」透過流程感知模型、定價細節和企業市場占有率分析解答了這些問題。該報告可用於量化各類別的需求、制定產品藍圖、設定定價和合約目標,以及優先進行培訓和支援計劃,從而加速產品推廣應用。
目錄
圖表清單
圖表列表
全球胃腸內視鏡設備市場概覽
競爭分析
新興市場與技術
市場趨勢
市場趨勢
流程分段
市場區隔
目標區域
重要報告更新
版本歷史記錄
調查方法
全球關稅的影響
全球胃腸內視鏡設備市場概覽
胃腸內視鏡市場
膠囊內視鏡市場
支架置入和擴張市場
經內視鏡逆行性膽胰管攝影術設備市場
切片檢查鉗和息肉切除勒除器市場
EUS針頭市場
內視鏡黏膜下剝離刀市場
止血設備市場
經腸營養裝置市場
回流防止裝置市場
The global gastrointestinal endoscopic device market was valued at nearly $16.3 billion in 2025. It is expected to grow at a compound annual growth rate of 4.0 percent to reach over $21.5 billion by 2031.
This report covers GI endoscopes, capsule endoscopy, stenting and dilation devices, ERCP devices, biopsy forceps and polypectomy snares, EUS needles, endoscopic submucosal dissection (ESD) knives, hemostasis devices, enteral feeding devices, and anti-reflux devices. The study quantifies unit sales, average selling prices (ASPs), market size, growth rates, and company shares, and analyzes procedure volumes, growth drivers and limiters, recent mergers and acquisitions, product portfolios, and competitive dynamics. Forecasts extend to 2031 with historical data to 2021.
Growth is supported by rising screening and early detection programs, an aging global population, and technology upgrades across imaging, therapeutic accessories, and single-use platforms. As emerging regions expand healthcare access, procedure volumes are expected to increase across diagnostic colonoscopy, ERCP, EUS, and therapeutic GI interventions.
Market Overview
Gastrointestinal endoscopy is central to the detection and treatment of GI disease. Colonoscopy is the anchor procedure for colorectal cancer screening and polyp removal, while upper GI endoscopy addresses bleeding, strictures, and reflux-related pathology. Therapeutic procedures such as ERCP, ESD, and EUS-guided interventions have broadened the role of endoscopy beyond diagnosis to include complex therapy.
Market value is shaped by a mix of capital equipment, reusable and single-use devices, and high-volume consumables. The capital base includes GI endoscopes and video processors. High-throughput categories such as biopsy forceps, polypectomy snares, stents, balloons, and hemostasis tools drive recurring revenue. Capsule endoscopy adds a non-invasive pathway for small bowel imaging, while enteral feeding devices support nutrition management in acute and chronic care.
Providers are upgrading from standard imaging to HD and HD+, with selective adoption of 4K and magnification where budgets allow. Single-use endoscopes are gaining attention for infection control and workflow advantages in targeted settings. At the same time, structured national screening programs are expanding the population that enters GI care pathways, which supports steady procedure growth.
Cost control remains a defining factor. Group purchasing organizations and tender models reduce ASPs in mature markets, while hospital budgets drive staged adoption of single-use devices. Even so, demand for advanced therapy has continued to expand as clinicians pursue less invasive alternatives to open surgery and as evidence for endoscopic therapy grows.
Emerging regions in Asia-Pacific and Latin America are set to contribute a larger share of global volumes as infrastructure improves, training expands, and public awareness increases. In these markets, growth in endoscopy suites and imaging fleets will support both diagnostic and therapeutic procedures.
Market Drivers
Incidence of cancer
Colorectal cancer is one of the most common cancers worldwide and a leading cause of cancer-related death. Aging demographics and better awareness drive more people into screening programs. Colonoscopy every five to ten years allows the detection and removal of precancerous polyps, which lowers cancer risk. Rising participation in screening supports sustained demand for colonoscopes, biopsy tools, snares, and hemostasis devices.
Screening and early detection programs
Policy changes and national programs have widened the eligible screening population. In the United States, the USPSTF lowered the recommended starting age for colorectal screening from 50 to 45 years, which increases the number of screening colonoscopies. The U.K. NHS is reducing the starting age for bowel screening from 60 to 50. In South Korea, the national program uses biennial FIT with colonoscopy follow-up for positive tests. These programs create predictable, recurring volumes that support stable purchasing of scopes and consumables, and they drive adoption of higher-performance imaging to improve polyp detection.
New technological developments
Imaging upgrades to HD and HD+, along with magnification and better optics, improve diagnostic accuracy. Flexible scopes have become easier to maneuver, and specialized accessories allow more precise therapy. Single-use platforms reduce cross-contamination risk and simplify reprocessing, which can be valuable for infection control and staffing constraints. Notable products include Boston Scientific's Exalt Model D single-use duodenoscope and Ambu's aScope portfolio. In parallel, 3D visualization and 4K imaging are being evaluated for specific use cases. As these technologies mature and cost barriers decline, unit sales and procedure counts are expected to rise.
Expansion in emerging regions
Healthcare investment in Asia-Pacific and Latin America is increasing the number of endoscopy suites, training programs, and referral pathways. Urbanization and higher incomes improve access to care. As awareness of GI disease rises and screening becomes more common, procedure volumes increase, lifting demand for endoscopes, ERCP devices, EUS needles, and hemostasis tools.
Therapeutic breadth and efficiency
Endoscopy now treats bleeding, removes stones, dilates strictures, resects early cancers, and closes defects. Broader therapy expands the addressable market beyond screening and diagnosis. Efficiency gains through AI-assisted polyp detection, improved hemostasis devices, and faster ERCP stone-management tools shorten procedure time and improve throughput, which supports adoption.
Market Limiters
Group purchasing organizations
GPOs and tenders consolidate demand and push down prices, which makes it difficult for smaller manufacturers to compete. Volume commitments and aggressive discounts favor large vendors with broad portfolios. This dynamic limits the market access of niche players and compresses ASPs, particularly in high-volume consumables.
Screening alternatives
Less invasive screening methods such as FIT-DNA, blood-based tests, and capsule colonoscopy are gaining interest. These options can reduce barriers to initial screening. However, a positive result still requires a colonoscopy for confirmation and treatment, which preserves the central role of endoscopy. Even with some diversion of initial tests, downstream colonoscopy volumes remain necessary, which helps limit the impact on colonoscope unit sales.
Hesitation to adopt new technology
Clinician adoption of new devices is cautious. Many providers seek robust evidence of clinical benefit and workflow fit before changing practice. Cost and training time also slow uptake. Single-use platforms, for example, must justify expense with infection control or efficiency benefits. Over time, favorable studies and better procurement models can stimulate adoption, but the path is gradual.
Budget constraints and reprocessing investments
Hospitals with recent investments in reprocessing and capital fleets will require clear value cases to switch to single-use devices or premium accessories. Budgets in emerging regions prioritize high-impact items first, which can delay adoption of advanced imaging or specialty tools.
Market Coverage and Data Scope
Care settings include hospitals, outpatient endoscopy centers, ambulatory surgery centers, and specialty clinics.
Markets Covered and Segmentation
Gastrointestinal Endoscope Market
Capsule Endoscopy Market
Stenting and Dilation Market
Endoscopic Retrograde Cholangiopancreatography (ERCP) Device Market
Biopsy Forceps and Polypectomy Snares Market
EUS Needle Market
Endoscopic Submucosal Dissection Knife Market
Hemostasis Device Market
Enteral Feeding Device Market
Anti-Reflux Device Market
Each segment is analyzed for market values, ASPs, units, growth rates, and company shares with historical trends and forecast outlook to 2031.
Competitive Analysis
Olympus held the leading position in the GI endoscope market and in the ESD knife segment. The company also maintained strong shares in capsule endoscopy, ERCP devices, biopsy forceps, polypectomy snares, EUS needles, and hemostasis devices. This breadth secured the top overall market share. Olympus continues to benefit from a reputation for durable image quality, a large installed base, and comprehensive service and training support.
Boston Scientific led more accessory segments than any other competitor in 2025. The company held the top share in stenting and dilation devices, ERCP devices, biopsy forceps and polypectomy snares, EUS needles, and hemostasis devices, and it maintained a competitive position in ESD knives. Growth is supported by the AXIOS(TM) lumen-apposing stent for transluminal drainage and by the Exalt Model D single-use duodenoscope, which addresses reprocessing challenges in ERCP. These products help drive procedure efficiency and infection control, supporting continued adoption.
Fujifilm ranked third overall, supported by the second-largest share of the GI endoscope market. Strong imaging capabilities, product reliability, and a growing therapeutic accessory portfolio have advanced its standing in hospitals and outpatient centers. The company placed just ahead of Avanos Medical in total share.
Other participants compete across select niches such as capsule endoscopy, enteral feeding, and anti-reflux devices. In price-sensitive regions, local manufacturers supply value-oriented consumables, while global leaders retain advantages in imaging, training, and full-line service.
Technology and Practice Trends
These trends support higher throughput, more consistent outcomes, and a broader range of treatable conditions within the endoscopy suite.
Geography
This edition provides global coverage across North America, Europe, Asia-Pacific, Latin America, the Middle East, and Africa.
Where are the largest and fastest-growing opportunities within the GI endoscopic device market.
How screening programs and aging demographics will shape demand for colonoscopy and therapeutic endoscopy.
Which technology upgrades will gain share, including single-use platforms, AI-assisted tools, and advanced imaging.
How GPOs and tender models affect pricing and market access for both large and small manufacturers.
What procedure shifts are expected across ERCP, EUS, ESD, and capsule endoscopy, and how these affect accessory consumption.
How Olympus, Boston Scientific, and Fujifilm are positioned across capital and accessory segments.
What risks could slow adoption, including budget limits, screening alternatives, and clinician hesitancy.
How suppliers can align training, service, and inventory to support growth in emerging regions.
The Global Gastrointestinal Endoscopic Device Market Report from iData Research answers these questions with procedure-aware models, pricing detail, and company share analysis. Use it to quantify demand by category, plan product roadmaps, set pricing and contracting targets, and prioritize training and support programs that speed adoption.
Table Of Contents
List Of Figures
List Of Charts
Global Gastrointestinal Endoscopic Device Market Overview
Competitive Analysis
Emerging Markets And Technologies
Market Trends
Market Developments
Procedure Segmentation
Market Segmentation
Regions Included
Key Report Updates
Version History
Research Methodology
Impact Of Global Tariffs
Global Gastrointestinal Endoscopic Device Market Overview
Gastrointestinal Endoscope Market
Capsule Endoscopy Market
Stenting & Dilation Market
Endoscopic Retrograde Cholangiopancreatography Device Market
Biopsy Forceps And Polypectomy Snares Market
Eus Needle Market
Endoscopic Submucosal Dissection Knife Market
Hemostasis Device Market
Enteral Feeding Device Market
Anti-Reflux Device Market